Webinars & e-learning courses All webinars

Approach to canine mast cell tumours and soft tissue sarcomas

Approach to canine mast cell tumours and soft tissue sarcomas
Approach to canine mast cell tumours and soft tissue sarcomas

Mast cell tumours (MCT) and soft tissue sarcomas (STS) are some of the most common tumours encountered in small animal practice. Although surgical removal is often the most appropriate initial treatment, questions like whether or not to perform staging tests prior to surgery, identification of cases where surgery may not be recommended, treatment options for non-surgical cases, interpretation of prognostic factors and the best approach for follow up can be more challenging. In this webinar we will discuss initial diagnosis of canine MCT and STS, when and which staging tests are appropriate for different cases, interpretation of histopathology reports and grading schemes, and non-surgical treatment options. We will discuss in more depth the use of receptor tyrosine kinase inhibitors such as Palladia in canine MCT.

This webinar is sponsored by ASAP Laboratory.

Recording from 31.07.2018

Speaker:

Claire_Canonn_portrait_photo.jpg

Claire Cannon

Claire Cannon BVSc (hons) DACVIM (Oncology) MANZCVS

Claire graduated from the University of Melbourne in 2003 and spent several years in general practice in Australia and the United Kingdom before deciding to specialise. During her internship, she worked veterinary oncologists for the first time and realised that there are always options for animals with cancer, ranging from surgery, radiation therapy and chemotherapy to palliative or comfort care, and she decided that oncology was the career path for her. She moved to the United States in 2009 to undertake a residency in veterinary oncology at the University of Minnesota. She became board certified in 2013 and went on to undertake additional training in research. She was an Assistant Professor at the University of Tennessee from 2013-2015 and the University of Minnesota from 2015-2017. She has authored multiple peer-reviewed journal articles and presented her research at several international conferences. Claire is delighted to be home in Australia and at U-Vet Animal Hospital. She is passionate about providing excellent care to all animals with cancer, and their owners, with a focus on maintaining the best quality of life possible for her patients. She is also excited to contribute to the training of our future veterinarians and to continue her research.

Booking information

Duration: 1:03 h
Speaker: Claire Cannon
from 1
54.90 US$
(incl. tax)

You might also be interested in

paraneoplastic-syndrome-1.jpeg
Valerie J. Poirier
0:45 h

Paraneoplastic Syndrome

Cancer can do anything..... Paraneoplastic syndrome are symptoms that occur at sites distant from a tumour or its metastasis. During this seminar, we will explore the categories of paraneoplastic syndromes and explain the mechanisms of those where it is elucidated. We will look at the comparative aspect of paraneoplastic syndrome in human medicine.
ICC image small.jpg
Sue Jaensch
0:50 h

Advanced diagnostics in canine and feline lymphoma.

So you have a diagnosis of lymphoma in your small animal patient. What next?  Classification of lymphoma is increasingly important for both prognostic and therapeutic decision making. This webinar will discuss diagnostic options to optimise the diagnostic process in your patient.  Modalities discussed will include immunocytochemistry, immunohistochemistry, flow cytometry and PARR. 
staging-the-oncology-patient.png
Laura Brockley
0:57 h

Staging the Oncology Patient

Staging is one of the most important components of oncology case management. It involves determining the extent of local disease along with the presence or absence of regional or distant metastasis. The results of staging are used to give more accurate and informed treatment options along with prognostic information for each oncology patient. Some of the biggest challenges in staging is to consider how much staging is required for each case, which are the most appropriate tests, and if the results of these tests will impact treatment options and prognosis. I will discuss this information in a case-based and evidence-based approach, focusing on some of the more common cancers including canine mast cell tumours, lymphoma, oral tumours and apocrine gland anal sac adenocarcinomas.